BioLineRx (BLRX) Income towards Parent Company (2023 - 2025)
Historic Income towards Parent Company for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.9 million.
- BioLineRx's Income towards Parent Company rose 4941.52% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year increase of 5725.76%. This contributed to the annual value of -$19.3 million for FY2024, which is 5942.77% up from last year.
- Latest data reveals that BioLineRx reported Income towards Parent Company of -$1.9 million as of Q3 2025, which was up 4941.52% from -$2.0 million recorded in Q2 2025.
- BioLineRx's Income towards Parent Company's 5-year high stood at -$1.9 million during Q3 2025, with a 5-year trough of -$19.5 million in Q4 2023.
- Its 3-year average for Income towards Parent Company is -$6.7 million, with a median of -$5.4 million in 2024.
- Data for BioLineRx's Income towards Parent Company shows a peak YoY increase of 6734.38% (in 2024) and a maximum YoY decrease of 3149.2% (in 2024) over the last 5 years.
- BioLineRx's Income towards Parent Company (Quarter) stood at -$19.5 million in 2023, then skyrocketed by 59.28% to -$7.9 million in 2024, then skyrocketed by 76.03% to -$1.9 million in 2025.
- Its Income towards Parent Company was -$1.9 million in Q3 2025, compared to -$2.0 million in Q2 2025 and -$2.0 million in Q1 2025.